Figure 4. Summary of responses. (A) Duration of nemvaleukin plus pembrolizumab therapy (part C) for patients in PD-(L)1 inhibitor-unapproved cohort.* (B) Duration of nemvaleukin plus pembrolizumab therapy (part C) for patients in PD-(L)1 inhibitor-approved cohort.* *PD-(L)1 inhibitor-approved/unapproved indication based on US FDA prescribing information at the time of the study design and could have changed over time. Responses per investigator-assessed Response Evaluation Criteria in Solid Tumors V.1.1. Swimmer plots show both confirmed and unconfirmed responses. BEV, bevacizumab; BL, bladder cancer; BR, breast cancer; CBP, carboplatin; CDDP, cisplatin; CE, cervical cancer; CO, colorectal cancer; CR, complete response; DOC, docetaxel; EA, esophageal adenocarcinoma; ER, estrogen receptor; FDA, Food and Drug Administration; GEM, gemcitabine; HER, human epidermal growth factor; Mo, month; NIR, niraparib; NSCLC, non–small-cell lung cancer; PAC, paclitaxel; PCA, paclitaxel albumin; PD, progressive disease; PLD, pegylated liposomal doxorubicin hydrochloride; PR, partial response; SCC, squamous cell carcinoma; SCLC, small-cell lung cancer; SD, stable disease; TAM, tamoxifen; TOP, topotecan; uPR, unconfirmed partial response.